Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 42, 2016, Pages E6409-E6417

  McFadden, David G ^a,h   Politi, Katerina ^b,c   Bhutkar, Arjun ^a   Chen, Frances K ^a   Song, Xiaoling ^c,i   Pirun, Mono ^d   Santiago, Philip M ^a   Kim Kiselak, Caroline ^a   Platt, James T ^c   Lee, Emily ^e   Hodges, Emily ^e   Rosebrock, Adam P ^e,j   Bronson, Roderick T ^f   Socci, Nicholas D ^d   Hannon, Gregory J ^e,g,k   Jacks, Tyler ^a   Varmus, Harold ^d,l  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE CANCER CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Simons Center for Quantitative Biology   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ SHANGHAITECH UNIVERSITY   (China)

^j UNIVERSITY OF TORONTO   (Canada)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^l WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

EGFR; Exome; GEMM; KRAS; MYC

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; CARCINOGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASE PAIRING; CHROMOSOME; CHROMOSOME LOSS; CLONE; CONTROLLED STUDY; DISEASE MODEL; EGFR GENE; EXOME; GENE DOSAGE; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ENGINEERING; GENOTYPE; KRAS GENE; LUNG ADENOCARCINOMA; MOUSE; MOUSE MODEL; NONHUMAN; ONCOGENE; ONCOGENE MYC; PRIORITY JOURNAL; ADENOCARCINOMA; ANIMAL; CELL TRANSFORMATION; COPY NUMBER VARIATION; DNA MUTATIONAL ANALYSIS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; LUNG TUMOR; MUTATION; ONCOGENE RAS; PATHOLOGY; POINT MUTATION; RECEIVER OPERATING CHARACTERISTIC; TRANSGENIC MOUSE; WHOLE EXOME SEQUENCING;

ADENOCARCINOMA; ANIMALS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; GENE DOSAGE; GENES, MYC; GENES, RAS; GENOME-WIDE ASSOCIATION STUDY; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; MUTATION; POINT MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; ROC CURVE; WHOLE EXOME SEQUENCING;

EID: 84991608512     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1613601113     Document Type: Article

References (51)

1. Govindan R, et al. (2012) Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150(6):1121-1134.
2. Imielinski M, et al. (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150(6):1107-1120.
3. Politi K, Herbst RS (2015) Lung cancer in the era of precision medicine. Clin Cancer Res 21(10):2213-2220.
4. Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543-550.
5. Ding L, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069-1075.
6. Sun S, Schiller JH, Gazdar AF (2007) Lung cancer in never smokers - a different disease. Nat Rev Cancer 7(10):778-790.
7. Fisher GH, et al. (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15(24):3249-3262.
8. Jackson EL, et al. (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15(24):3243-3248.
9. Ji H, et al. (2006) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9(6):485-495.
10. Politi K, et al. (2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to downregulation of the receptors. Genes Dev 20(11):1496-1510.
11. Oliver TG, et al. (2010) Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 24(8):837-852.
12. Politi K, Fan PD, Shen R, Zakowski M, Varmus H (2010) Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis Model Mech 3(1-2):111-119.
13. Winslow MM, et al. (2011) Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473(7345):101-104.
14. Holstege H, et al. (2010) Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers. BMC Cancer 10:455.
15. Maser RS, et al. (2007) Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447(7147):966-971.
16. Sweet-Cordero A, et al. (2006) Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer 45(4):338-348.
17. To MD, et al. (2011) Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer. Mol Cancer Res 9(10):1339-1345.
18. Varela I, et al. (2010) Somatic structural rearrangements in genetically engineered mouse mammary tumors. Genome Biol 11(10):R100.
19. Nassar D, Latil M, Boeckx B, Lambrechts D, Blanpain C (2015) Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nat Med 21(8):946-954.
20. McCreery MQ, et al. (2015) Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. Nat Med 21(12):1514-1520.
21. Calbó J, Meuwissen R, van Montfort E, van Tellingen O, Berns A (2005) Genotype-phenotype relationships in a mouse model for human small-cell lung cancer. Cold Spring Harb Symp Quant Biol 70:225-232.
22. Dooley AL, et al. (2011) Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev 25(14):1470-1475.
23. McFadden DG, et al. (2014) Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156(6):1298-1311.
24. Westcott PM, et al. (2015) The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517(7535):489-492.
25. Jackson EL, et al. (2005) The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65(22):10280-10288.
26. Tran PT, et al. (2008) Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One 3(5):e2125.
27. Podsypanina K, Politi K, Beverly LJ, Varmus HE (2008) Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci USA 105(13):5242-5247.
28. Kim SY, Speed TP (2013) Comparing somatic mutation-callers: Beyond Venn diagrams. BMC Bioinformatics 14:189.
29. Cibulskis K, et al. (2013) Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31(3):213-219.
30. Ewing AD, et al.; ICGC-TCGA DREAM Somatic Mutation Calling Challenge participants (2015) Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. Nat Methods 12(7):623-630.
31. DuPage M, Dooley AL, Jacks T (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4(7):1064-1072.
32. Johnson L, et al. (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410(6832):1111-1116.
33. Francis SP, et al. (2015) A short splice form of Xin-actin binding repeat containing 2 (XIRP2) lacking the Xin repeats is required for maintenance of stereocilia morphology and hearing function. J Neurosci 35(5):1999-2014.
34. Scheffer DI, et al. (2015) XIRP2, an actin-binding protein essential for inner ear hair-cell stereocilia. Cell Reports 10(11):1811-1818.
35. Wang Q, et al. (2010) Essential roles of an intercalated disc protein, mXinbeta, in postnatal heart growth and survival. Circ Res 106(9):1468-1478.
36. Wu C, et al. (2009) BioGPS: An extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol 10(11):R130.
37. Fujimoto A, et al. (2015) Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun 6:6120.
38. Unni AM, Lockwood WW, Zejnullahu K, Lee-Lin SQ, Varmus H (2015) Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. eLife 4:e06907.
39. Ota S, Zhou ZQ, Link JM, Hurlin PJ (2009) The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects. Hum Mol Genet 18(14):2609-2621.
40. Tchaicha JH, et al. (2014) Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Res 74(17):4676-4684.
41. Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5(4):557-572.
42. Taylor BS, et al. (2008) Functional copy-number alterations in cancer. PLoS One 3(9):e3179.
43. Feldser DM, et al. (2010) Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468(7323):572-575.
44. Soucek L, et al. (2013) Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev 27(5):504-513.
45. Weir BA, et al. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450(7171):893-898.
46. Maddalo D, et al. (2014) In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516(7531):423-427.
47. Sánchez-Rivera FJ, Jacks T (2015) Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer 15(7):387-395.
48. Sánchez-Rivera FJ, et al. (2014) Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 516(7531):428-431.
49. Rizvi NA, et al. (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124-128.
50. DuPage M, et al. (2011) Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 19(1):72-85.
51. Rodrigue S, et al. (2010) Unlocking short read sequencing for metagenomics. PLoS One 5(7):e11840.